Patents by Inventor Uta Friederike LESSEL

Uta Friederike LESSEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL TETRAZOLES
    Publication number: 20240101561
    Abstract: This invention relates to tetrazoles and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: October 14, 2020
    Publication date: March 28, 2024
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Uta Friederike LESSEL, Jens WILLWACHER
  • Substituted 3-phenoxyazetidin-1-yl-pyrazines
    Patent number: 11780827
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: October 10, 2023
    Assignees: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • Thienopyrimidones
    Patent number: 11578080
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: February 14, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Annekatrin Charlotte Heimann, Uta Friederike Lessel, Jens Willwacher
  • SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES
    Publication number: 20220356172
    Abstract: The invention relates to substituted 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) for use as a medicament, pharmaceutical compositions comprising the 3-phenoxyazetidin-1-yl-pyrazines of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.
    Type: Application
    Filed: March 29, 2021
    Publication date: November 10, 2022
    Applicants: Boehringer Ingelheim International GmbH, Arena Pharmaceuticals, Inc.
    Inventors: Kai Gerlach, Graeme Semple, Yifeng Xiong, Barbara Bertani, Marco Ferrara, Giacomo Fossati, Scott Hobson, Uta Friederike Lessel, Frank Runge, Ursula Mueller-Vieira, Julian Wippich
  • N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides
    Patent number: 11324724
    Abstract: The present invention relates to novel N-(2,2-difluoroethyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: May 10, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Niklas Heine, Uta Friederike Lessel, Stefan Scheuerer
  • N-[(pyrimidinylamino)propanyl]-,n-[pyridylamino)propanyl]- and n-[(pyrazinylaminol)propanyl]arylcarboxamides
    Patent number: 11236072
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)-propanyl]- and N-[(Pyrazinylamino)¬propanyl]arylcarboxamide such as compound The present invention also relates to derivatives of such compounds, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: February 1, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Friederike Lessel, Radoslaw Lipinski, Stefan Scheuerer
  • Novel Thienopyrimidones
    Publication number: 20210395267
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: September 1, 2021
    Publication date: December 23, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Annekatrin Charlotte HEIMANN, Uta Friederike LESSEL, Jens WILLWACHER
  • Novel Thienopyrimidones
    Publication number: 20210107919
    Abstract: This invention relates to thienopyrimidinones and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 15, 2021
    Inventors: Martin Thomas FLECK, Florian Paul Christian BINDER, Georg DAHMANN, Joerg P. HEHN, Annekatrin Charlotte HEIMANN, Uta Friederike LESSEL
  • NOVEL N-(2,2-DIFLUOROETHYL)-N-[(PYRIMIDINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
    Publication number: 20200283418
    Abstract: The present invention relates to novel N-(2,2-difluoroehtyl)-N-[(Pyrimidinylamino)propanyl]-arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: September 26, 2018
    Publication date: September 10, 2020
    Inventors: Doris RIETHER, Niklas HEINE, Uta Friederike LESSEL, Stefan SCHEUERER
  • NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-,N-[PYRIDYLAMINO)PROPANYL]- AND N-[(PYRAZINYLAMINOL)PROPANYL]ARYLCARBOXAMIDES
    Publication number: 20200231575
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]-, N-[(Pyridylamino)propanyl]- and N-[(Pyrazinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: July 26, 2018
    Publication date: July 23, 2020
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta Friederike LESSEL, Radoslaw LIPINSKI, Stefan SCHEUERER
  • N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides
    Patent number: 9884854
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 6, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Doris Riether, Marco Ferrara, Niklas Heine, Uta Friederike Lessel, Janet Rachel Nicholson, Anton Pekcec, Stefan Scheuerer
  • NOVEL N-[(PYRIMIDINYLAMINO)PROPANYL]-AND N [(PYRAZINYLAMINO)PROPANYL]ARYLCARBOXAMIDES
    Publication number: 20170298053
    Abstract: The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.
    Type: Application
    Filed: April 12, 2017
    Publication date: October 19, 2017
    Inventors: Doris RIETHER, Marco FERRARA, Niklas HEINE, Uta Friederike LESSEL, Janet Rachel NICHOLSON, Anton PEKCEC, Stefan SCHEUERER